Catalyst Wire Dossier Catalyst Wire Dossier

Ofatumumab (Kesimpta)

ofatumumab · Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Ofatumumab (Kesimpta), covering 2025-03-25 to 2025-03-25. Get the full timeline:

Most recent: Clinical Trial Update: A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data

See pricing